ESC NEUBASE THERAPEUTI

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

NBSE.ESC

ARKG

LABU

Atamyo Therapeutics has reported promising results from its ATA-200 gene therapy trial for LGMD-R5 limb-girdle muscular dystrophy. Four patients have been treated, showing safety and significant efficacy, including over 90% muscle fiber expression of the therapeutic gene and reduced muscle damage biomarkers. The trial, led by Dr. Barry Byrne at the University of Florida, aims to evaluate the therapy's safety and effectiveness in children aged 6 to 13. Initial results are encouraging, with further data expected in the coming months. Atamyo Therapeutics focuses on innovative gene therapies for rare muscular dystrophies.

MorningStar

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-Girdle Muscular Dystrophy

TOVX

SBIO

Valerio Therapeutics has launched InVimmune, a new company focused on developing differentiated in vivo cell therapy approaches for oncology, fibrosis, and autoimmune diseases. The initiative aims to address high unmet medical needs in oncology, leveraging Valerio's proprietary technology platforms. InVimmune will be supported by a dedicated Oncology Scientific Advisory Board, including notable experts. The company emphasizes its innovative immune reprogramming strategy and plans to provide further updates on its development.

Theriva Biologics

VanEck Biotech ETF

ALPS Medical Breakthrough

Innate Pharma SA

Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches

426CVR015TMP

COEP

SEELQ

SEEL

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Hepion Pharmaceuticals, Inc.

Coeptis Therapeutics

SEELOS THERAPEUTICS INC

Seelos Therapeutics

Seaport ENT

Seaport and Hemab target $180m IPOs as biotech listings accumulate

KPTI

LLYZ

Eli Lilly is nearing a $2 billion acquisition of Kelonia Therapeutics to enhance its cancer pipeline. The deal, expected to be announced soon, may include milestone payments. Kelonia focuses on a next-generation CAR T therapy for multiple myeloma, aiming to simplify treatment processes. Despite raising under $60 million and being valued at over $100 million in 2022, Lilly's investment reflects its long-term potential in the $240 billion oncology market. Kelonia's lead program has FDA clearance for Phase 1 trials with up to 40 patients.

GuruFocus

Karyopharm Therap

Defiance Daily Target 2X Short LLY ETF

Direxion Daily LLY Bear 1X Shares

iShares US Pharma

Defiance Daily Target 2X Long LLY ETF

Eli Lilly

Eli Lilly Moves To Strengthen Cancer Pipeline

GRTX

Kailera Therapeutics Announces Pricing of Initial Public Offering | KLRA Stock News

StockTitan

Galera Therapeutics

Kailera Therapeutics Announces Pricing of Initial Public Offering | KLRA Stock News

ATXS

Egetis Therapeutics has appointed Tiago Nunes, MD, PhD, as Chief Medical Officer, effective May 1, 2026. Nunes, previously Senior VP at Mirum Pharmaceuticals, brings extensive experience in rare disease therapeutics. CEO Nicklas Westerholm expressed excitement about Nunes joining the team as they prepare for the U.S. launch of Emcitate® (tiratricol), the first treatment for MCT8 deficiency. Outgoing CMO Kristina Sjöblom Nygren will assist in the transition until Emcitate® is approved in the U.S. The company focuses on developing treatments for serious diseases with unmet medical needs.

Astria Therapeutics

Egetis Appoints Tiago Nunes as Chief Medical Officer

BTMD

MindBio Therapeutics Corp. has successfully closed a private placement, raising $1,437,828.87 by issuing 2,396,381 units at $0.60 each. The funds will be used to enhance the development of its intoxication detection technology. Additionally, the company has engaged two service providers for promotional and marketing services to increase public awareness and investor reach. The engagements include cash compensation and will run for one year. All securities issued are subject to resale restrictions for four months and are pending final regulatory approvals.

ESC NEUBASE THERAPEUTI(NBSE.ESC.US)

Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-Girdle Muscular Dystrophy

Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches

Seaport and Hemab target $180m IPOs as biotech listings accumulate

Eli Lilly Moves To Strengthen Cancer Pipeline

Kailera Therapeutics Announces Pricing of Initial Public Offering | KLRA Stock News

Egetis Appoints Tiago Nunes as Chief Medical Officer

MindBio Announces Closing of Private Placement